News | December 05, 2022
Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)